Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study

Springer Science and Business Media LLC - Tập 13 Số 1 - Trang 65 - 2014
Kohei Kaku1, Hirotaka Watada2, Yasuhiko Iwamoto3, Kazunori Utsunomiya4, Yasuo Terauchi5, Kazuyuki Tobe6, Yukio Tanizawa7, Eiichi Araki8, Masamichi Ueda9, Hideki Suganami10, Daisuke Watanabe11
1Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan
2Department of Endocrinology & Metabolism, Juntendo University Graduate School of Medicine, Bunkyo-ku, Japan
3Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Japan
4Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Japan
5Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Kanazawa-ku, Japan
6The First Department of Internal Medicine, University of Toyama, Toyama, Japan
7Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, Yamaguchi University Graduate School of Medicine, Ube, Japan
8Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
9Clinical Research Planning Department, Chugai, Chuo-ku, Japan
10Clinical Data Science Department, Biostatistics Section, Kowa, Chuo-ku, Japan
11Research & Development, Clinical Sciences & Operations, Biostatistics & Programming, Biostatistics, Shinjuku-ku, Japan

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.2337/dc12-0413

10.1111/dom.12149

10.1111/dom.12054

10.1210/jc.2011-2260

10.1136/bmj.d410

10.7326/0003-4819-159-4-201308200-00007

10.1038/nrd3180

10.1111/j.1523-1755.2005.00053.x

10.1016/j.ymgme.2004.01.018

10.1385/CBB:36:2-3:115

10.1124/jpet.112.191593

10.1186/1475-2840-12-129